Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment   source : Investors.ovidrx.com    save search
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
Published: 2021-03-03 (Crawled : 10:48) - investors.ovidrx.com
TAK | News | $13.41 0.37% 1M twitter stocktwits trandingview |
Health Technology
 | | O: 2.03% H: 1.14% C: 0.68%
OVID | $3.21 1.91% 25K twitter stocktwits trandingview |
Health Technology
 | | O: 58.45% H: 1.28% C: -13.86%
treatment commercialization children syndros dravet syndrome
Gainers vs Losers
87% 13%

Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M twitter stocktwits trandingview |

AGBA | $2.74 119.2% 52M twitter stocktwits trandingview |
Finance
CZOO | $9.07 81.76% 22M twitter stocktwits trandingview |

EDBL | News | $6.56 74.47% 1.8M twitter stocktwits trandingview |

OPRT | News | $3.37 49.78% 8.9M twitter stocktwits trandingview |
Finance
MTC | $2.21 41.67% 5.6M twitter stocktwits trandingview |
Technology Services
VNRX | $0.7945 32.42% 3.1M twitter stocktwits trandingview |
Health Technology
MLEC | $1.81 29.29% 2.8M twitter stocktwits trandingview |
n/a
BTCM | $3.45 27.78% 640K twitter stocktwits trandingview |
Arts, Entertainment, and Recrea...
PALI | $6.29 27.59% 22M twitter stocktwits trandingview |
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.